Small molecule peptide tablet for resisting breast cancer and breast cancer induced fatigue and preparation method of small molecule peptide tablet

By developing small-molecular peptide tablets that are anti-breast cancer and breast cancer-induced fatigue, the inhibitory effect of dipeptide structure and active peptides is used to solve the problems of fatigue symptoms and side effects in breast cancer treatment, and efficient anti-cancer and anti-fatigue effects are achieved , reduces damage to normal cells.

CN118903370AInactive Publication Date: 2024-11-08SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Patent Information

Application Number
CN202410945012.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Breast cancer treatment drugs often cause a variety of toxic side effects, especially fatigue symptoms, and the existing treatment methods are limited in efficacy, affecting the quality of life of patients.

Method used

Develop a small molecule peptide tablet that is anti-fatigue-induced by breast cancer and breast cancer. By constructing a dipeptide structure, it predicts potential targets, screens out active peptides that inhibit breast cancer and fatigue-related targets, and synthesizes them using Fmoc solid-phase synthesis method. Small molecule peptides, prepare tablets, combine gamma-aminobutyric acid, egg yolk lecithin, resveratrol, grape seed extract and dextrin to form tablets.

Benefits of technology

Significantly inhibit the progression and fatigue effect of breast cancer, reduce side effects, improve safety, enhance treatment effect, reduce damage to normal cells, and improve patients' quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903370A_ABST
    Figure CN118903370A_ABST
Patent Text Reader

Abstract

The invention discloses a small molecule peptide tablet for resisting breast cancer and breast cancer induced fatigue and a preparation method of the small molecule peptide tablet, and belongs to the technical field of biological medicines.The preparation method of the small molecule peptide tablet for resisting breast cancer and breast cancer induced fatigue comprises the following steps that a dipeptide structure is constructed; predicting a potential action target of the dipeptide; searching for action target information of breast cancer and fatigue related diseases; intersection of the found breast cancer and fatigue related disease action target and 400 dipeptide action targets is obtained, and 400 small peptide potential disease action targets are obtained; screening active peptides; synthesizing a small molecule peptide; and preparing the small molecule peptide tablet. The small molecule peptide for resisting breast cancer and breast cancer induced fatigue prepared by the invention has excellent cancer fatigue resistance and anticancer activity through the synergistic effect of auxiliary components such as gamma-aminobutyric acid, egg yolk lecithin, resveratrol, grape seed extract and dextrin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a small molecule peptide tablet for resisting breast cancer and breast cancer-induced fatigue and a preparation method thereof. Background Art

[0002] Breast cancer is the most common cancer in the world and one of the most common malignant tumors in women. In 2020, the number of new breast cancer cases worldwide was 2.26 million, and the number of deaths was 685,000. In China, there were about 415,000 new cases of breast cancer and 121,000 deaths, accounting for about 15% of all malignant tumors. At present, the treatment methods for breast cancer mainly include surgery, radiation, chemotherapy, endocrine therapy and targeted therapy. However, while treating breast cancer, the drugs used in clinical practice can also cause a variety of toxic side effects, such as fatigue. Fatigue is one of the main symptoms of breast cancer patients, which seriously affects their quality of life. The incidence of postoperative fatigue in breast cancer patients is as high as 58%. According to research data, 75% of breast cancer patients have significant fatigue 6 months after surgery. 12 months after surgery, the degree of fatigue has not been reduced. Fatigue and sleep disorders often occur together, which brings great inconvenience to patients' lives and work. At present, the treatment methods for postoperative fatigue after breast cancer surgery include drug therapy, psychological intervention, exercise therapy, etc., but they are often limited in efficacy and low in patient compliance. Small molecule peptides have attracted widespread attention due to their advantages such as high penetration, high biocompatibility, high stability and low toxic side effects. Small molecule peptides have many advantages as drugs. First, small molecule peptides can efficiently penetrate the cell membrane and reach the inside of the cell to exert their effects, unlike protein macromolecules that cannot penetrate the cell membrane. Small molecule peptides can also regulate multiple signaling pathways, thereby synergistically exerting multiple effects such as anti-tumor, anti-inflammatory, and anti-fatigue. In addition, the low toxic side effects of small molecule peptides allow them to be continuously administered without causing damage to normal cells, and have broad application prospects. From an anti-cancer perspective, small molecule peptides have the effects of maintaining brain function, promoting brain repair and brain cell generation, and regulating nerve conduction, thereby playing a role in anti-cancer fatigue. In addition, small molecule peptides can also regulate signaling pathways such as the mitochondrial apoptosis pathway and the extracellular signal-regulated kinase, thereby promoting cancer cell apoptosis, inhibiting cancer cell proliferation, migration and invasion, and thus playing a role in anti-breast cancer. Summary of the invention

[0003] In view of the problems and shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide a small molecule peptide tablet for resisting breast cancer and breast cancer-induced fatigue and a preparation method thereof. The small molecule peptide tablet for resisting breast cancer and breast cancer-induced fatigue prepared by the present invention has excellent anti-breast cancer and cancer-induced fatigue activity.

[0004] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0005] A method for preparing a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue comprises the following steps:

[0006] S1, construction of dipeptide structure;

[0007] S2. Predict potential targets of dipeptides;

[0008] S3. Find information on targets for breast cancer and fatigue-related diseases;

[0009] S4, taking the intersection of the breast cancer and fatigue-related disease targets found in step S3 and the 400 dipeptide targets in step S2, obtaining 400 potential disease targets of small peptides, and finally screening out cancer-related targets and fatigue-related targets;

[0010] S5. Use molecular docking method to screen active peptides with inhibitory effects on targets related to breast cancer and breast cancer-induced fatigue;

[0011] S6, synthesis of small molecule peptides;

[0012] S7. Preparation of small molecule peptide tablets.

[0013] Preferably, in step S1, 400 dipeptide structures are constructed using ChemDraw and Chem3D.

[0014] Preferably, in step S2, Pharmmapper software is used to predict potential dipeptide targets to obtain 400 dipeptide targets.

[0015] Preferably, in step S3, all target information of breast cancer and fatigue-related diseases is searched through GeneCards (https: / / www.genecards.org / ), OMIM (https: / / www.omim.org / ), DisGeNET (https: / / www.disgenet.org / ) and TTD (http: / / db.idrblab.net / ttd / ).

[0016] Preferably, the cancer-related targets finally screened out in step S4 are APAF1, BTK, INSR, and RAC1, and the fatigue-related targets are BTK, INSR, SELE, and SRC.

[0017] Further preferably, the APAF1 is apoptosis protease activating factor 1; BTK is Brucella tyrosine kinase; INSR is insulin receptor; RAC1 is Ras-related C3 botulinum toxin substrate 1; SELE is E-selectin; and SRC is proto-oncogene tyrosine protein kinase.

[0018] Preferably, in S5, the molecular docking method is used to screen active peptides with inhibitory potential on breast cancer and breast cancer-induced fatigue-related targets, comprising the following steps:

[0019] (1) Acquisition of 3D structures: The 3D structures of APAF1, BTK, INSR, RAC1, SELE, and SRC were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0020] (2) Molecular docking: After removing ligands and water molecules from APAF1, BTK, INSR, RAC1, SELE, and SRC in step (1), nonpolar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S1, and semi-flexible molecular docking of peptide with APAF1, peptide with BTK, peptide with INSR, peptide with RAC1, peptide with SELE, and peptide with SRC was performed using AutoDock 4.2 software;

[0021] (3) After molecular docking, active peptides that showed the best binding to breast cancer and breast cancer-induced fatigue-related targets were screened out based on the binding energy results.

[0022] Preferably, the anti-fatigue active peptides screened in S5 are FD, WD, EW, RE, PE, LD, WE, IE, YE, and YD;

[0023] The anticancer peptides are FD, WD, RE, YD, RD, EW, CD, PD, ED, and EE.

[0024] Preferably, in S6, the active peptides screened in step S5 are synthesized into small molecule peptides by using the Fmoc solid phase synthesis method in Shanghai Kepeptide Biotechnology Co., Ltd.

[0025] Preferably, the synthetic anti-fatigue small molecule peptide is FD, WD, EW, RE, PE, LD, WE, IE, YE, YD;

[0026] The anticancer small molecule peptides are FD, WD, RE, YD, RD, EW, CD, PD, ED, and EE.

[0027] The structural formula of the above small molecule peptide is as follows:

[0028]

[0029] Preferably, in step S7, one or more of the small molecule peptides synthesized in S6 are mixed with γ-aminobutyric acid, egg yolk lecithin, resveratrol, grape seed extract, and dextrin.

[0030] The present invention also provides small molecule peptide tablets for resisting breast cancer and breast cancer-induced fatigue prepared by the preparation method.

[0031] Preferably, the dosage form of the pharmaceutical agent is a tablet, which is prepared by mixing the above-mentioned substances, placing the mixture in a hopper, using a tablet press to tablet the mixture in the hopper, and taking out the tablets after tableting and packaging them.

[0032] Preferably, the tablet weighs 0.2-0.4 g.

[0033] Preferably, the present invention discloses a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue, comprising the following components: 0.5-1 parts of small molecule peptides (FD, WD, EW, RE, PE), 0.5-1 parts of small molecule peptides (FD, WD, RE, YD, RD), 0-0.5 parts of small molecule peptides (LD, WE, IE, YE, YD), 0-0.5 parts of small molecule peptides (EW, CD, PD, ED, EE), 1-3 parts of γ-aminobutyric acid, 1-3 parts of egg yolk lecithin, 1-3 parts of resveratrol, 1-3 parts of grape seed extract, and 4-20 parts of dextrin.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The present invention provides a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue, which shows obvious effects on preventing breast cancer progression and breast cancer-induced fatigue, and enhances the in-depth development and utilization of small molecule peptides. The small molecule peptide tablets provided by the present invention can be administered with different formulas according to the patient's physical condition and needs. Patients undergoing treatment can administer tablets with better anti-cancer effects, while cancer recovery patients can administer tablets with better anti-fatigue effects. The small molecule peptide tablets provided by the present invention have lower side effects and higher safety, and strong targeting, which not only improves the therapeutic effect, but also reduces damage to normal cells and tissues. In addition, the high safety characteristics of the tablets also make it an important auxiliary means for reducing side effects and improving the quality of life of patients in the treatment of breast cancer, and enhance the application potential of small molecule peptides in the medical field. In addition, the preparation process of the tablets is simple and easy to mass produce, which is conducive to their wide promotion and application in the medical market.

[0036] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 Figure 1 is a schematic diagram of the binding of anticancer peptides to targets, where: Figure 1 A in the figure is a schematic diagram of the binding of APAF1 and FD. Figure 1 B in the figure is a schematic diagram of the binding of APAF1 and WD. Figure 1 C in the figure is a schematic diagram of APAF1 binding to RE. Figure 1 D in the figure is a schematic diagram of the combination of BTK and FD. Figure 1E in the figure is a schematic diagram of the binding of BTK and WD. Figure 1 F in the figure is a schematic diagram of BTK binding to RE. Figure 1 G in the figure is a schematic diagram of the combination of INSR and FD. Figure 1 The H in the figure is a schematic diagram of the combination of INSR and WD. Figure 1 I in the figure is the schematic diagram of the combination of INSR and RE. Figure 1 J in the figure is a schematic diagram of the binding of RAC1 and FD. Figure 1 K in the figure is a schematic diagram of the binding of RAC1 to WD. Figure 1 L in the figure is a schematic diagram of the binding of RAC1 to RE;

[0038] Figure 2 Figure 1 is a schematic diagram of the binding of anti-fatigue active peptides to targets, where: Figure 2 A in the figure is a schematic diagram of the combination of INSR and EW. Figure 2 B in the figure is a schematic diagram of the combination of INSR and FD. Figure 2 C in the figure is a schematic diagram of the combination of INSR and WD. Figure 2 D in the figure is a schematic diagram of the combination of BTK and EW. Figure 2 E in the figure is a schematic diagram of the combination of BTK and FD. Figure 2 F in the figure is a schematic diagram of the combination of BTK and WD. Figure 2 G in the figure is a schematic diagram of the combination of SELE and EW. Figure 2 The H in the figure is a schematic diagram of the combination of SELE and FD. Figure 2 I in the figure is the schematic diagram of the combination of SELE and WD. Figure 2 J in the figure is a schematic diagram of the combination of SRC and EW. Figure 2 K in is the schematic diagram of the combination of SRC and FD. Figure 2 L in the figure is a schematic diagram of the combination of SRC and WD;

[0039] Figure 3 The effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue provided by the control group and Examples 1-4 on the survival rate of breast cancer cells;

[0040] Figure 4 The effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue provided by the control group and Examples 1-4 on the migration rate of breast cancer cells;

[0041] Figure 5 Statistical graph showing the effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue provided in the model group and Examples 1-4 on the weight changes of mice;

[0042] Figure 6 Statistical graph showing the effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue provided in the model group and Examples 1-4 on the swimming time of tumor-bearing mice;

[0043] Figure 7 Statistical graph showing the effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue provided in the model group and Examples 1-4 on the grip strength of tumor-bearing mice;

[0044] Figure 8 Statistical graphs showing the effects of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue on tumor weight provided for the model group and Examples 1-4;

[0045] Fig. 9 Statistical graph showing the effect of the small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue on tumor inhibition rate provided for the model group and Examples 1-4. DETAILED DESCRIPTION

[0046] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.

[0047] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.

[0048] The present invention provides a small molecule peptide for resisting breast cancer and breast cancer-induced fatigue and a preparation method thereof, comprising the following steps:

[0049] S1. Construction of dipeptide structures: 400 dipeptide structures were constructed using ChemDraw and Chem3D;

[0050] S2. Prediction of potential dipeptide targets: Pharmmapper software was used to predict potential dipeptide targets and 400 dipeptide targets were obtained;

[0051] S3. Search for target information of breast cancer and fatigue-related diseases: Search for all target information of breast cancer and fatigue-related diseases through GeneCards (https: / / www.genecards.org / ), OMIM (https: / / www.omim.org / ), DisGeNET (https: / / www.disgenet.org / ) and TTD (http: / / db.idrblab.net / ttd / ).

[0052] S4, taking the intersection of the breast cancer and fatigue-related disease targets found in step S3 and the 400 dipeptide targets in step S2 to obtain 400 potential disease targets of small peptides;

[0053] S5. Using the molecular docking method, screening active peptides that have inhibitory effects on targets related to breast cancer and breast cancer-induced fatigue includes the following steps:

[0054] (1) Acquisition of 3D structures: The 3D structures of APAF1, BTK, INSR, RAC1, SELE, and SRC were obtained from the RCSB database (http: / / www.rcsb.org / pdb);

[0055] (2) Molecular docking: After removing ligands and water molecules from APAF1, BTK, INSR, RAC1, SELE, and SRC in step (1), nonpolar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S1, and semi-flexible molecular docking of peptide with APAF1, peptide with BTK, peptide with INSR, peptide with RAC1, peptide with SELE, and peptide with SRC was performed using AutoDock 4.2 software;

[0056] (3) After molecular docking, the anti-fatigue active peptides were screened out according to the binding energy results, namely FD, WD, EW, RE, PE, LD, WE, IE, YE, and YD; the anti-cancer peptides were FD, WD, RE, YD, RD, EW, CD, PD, ED, and EE.

[0057] S6. Synthesis of small molecule peptides: Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S5 into small molecule peptides to obtain FD, WD, EW, RE, PE, LD, WE, IE, YE, YD anti-fatigue small molecule peptides and FD, WD, RE, YD, RD, EW, CD, PD, ED, EE anti-cancer small molecule peptides.

[0058] Example 1 This example provides a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue. One part of the above-mentioned synthesized small molecule peptides FD, WD, EW, RE, PE and one part of FD, WD, RE, YD, RD are mixed with 3 parts of γ-aminobutyric acid, 3 parts of egg yolk lecithin, 3 parts of resveratrol, 3 parts of grape seed extract, and 5 parts of dextrin, and placed in a hopper. A tablet press is used to tablet the mixture in the hopper, and the tablets after tableting are taken out and packaged. The weight of the tablets is 0.2 g.

[0059] Example 2 This example provides a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue. 0.5 parts of the above-mentioned synthesized small molecule peptides FD, WD, EW, RE, PE, LD, WE, IE, YE, YD are mixed with 0.5 parts of FD, WD, RE, YD, RD, EW, CD, PD, ED, EE and 3 parts of γ-aminobutyric acid, 3 parts of egg yolk lecithin, 3 parts of resveratrol, 3 parts of grape seed extract and 5 parts of dextrin, and the mixture is placed in a hopper. A tablet press is used to tablet the mixture in the hopper, and the tablets after tableting are taken out and packaged. The weight of the tablets is 0.2 g.

[0060] Example 3 This example provides a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue. 0.5 parts of the above-mentioned synthesized small molecule peptides FD, WD, EW, RE, PE, LD, WE, IE and 1 part of FD, WD, RE, YD, RD are mixed with 3 parts of γ-aminobutyric acid, 3 parts of egg yolk lecithin, 3 parts of resveratrol, 3 parts of grape seed extract, and 5 parts of dextrin, and placed in a hopper. A tablet press is used to tablet the mixture in the hopper, and the tablets after tableting are taken out and packaged. The weight of the tablets is 0.2 g.

[0061] Example 4 This example provides a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue. 1 part of the above-mentioned synthesized small molecule peptides FD, WD, EW, RE, PE are mixed with 0.5 parts of FD, WD, RE, YD, RD, EW, CD, PD, ED, EE and 3 parts of γ-aminobutyric acid, 3 parts of egg yolk lecithin, 3 parts of resveratrol, 3 parts of grape seed extract and 5 parts of dextrin, and placed in a hopper. A tablet press is used to tablet the mixture in the hopper, and the tablets after tableting are taken out and packaged. The weight of the tablets is 0.2 g.

[0062] Table 1 Screening of anticancer peptides

[0063]

[0064]

[0065] Table 2 Screening of anti-fatigue peptides

[0066]

[0067]

[0068] The effects of the tablets provided in the above embodiments were verified by the following tests:

[0069] 1. To verify the effect of Examples 1-4 on the survival rate of breast cancer cells, the experimental scheme was as follows: MCF-7 cells were cultured in a high-glucose formula medium supplemented with 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin at a culture temperature of 37° C. and a carbon dioxide concentration of 5%.

[0070] CCK-8 assay: The CCK-8 assay was used to detect the viability of breast cancer cells. Each breast cancer cell line (6 independent replicates) in the logarithmic growth phase was cultured at 5×10 3The cells were seeded into a 96-well plate at a density of 10 cells / well and then incubated overnight at 37°C. 2.0 mg / mL of Examples 1-4 were added to the cell culture medium and treated for 24 hours, with PBS as a control. Then 10 uL of CCK-8 solution reagent was added to each well and further incubated for 1 hour. The absorbance of the resulting solution was recorded at 450 nm using an ELISA reader (Varioskan Flash 2.4, Thermo Fisher Scientific, USA), and cell viability was expressed as a percentage of the control group. The results are shown in Figure 3 .

[0071] Depend on Figure 3 It can be seen that compared with the control group, the small molecule peptide tablets prepared in Example 1 can reduce the survival rate of breast cancer cells to 7.19%. The small molecule peptide tablets prepared in Example 2 can reduce the survival rate of breast cancer cells to 17.47%. The small molecule peptide tablets provided in Example 3 can reduce the survival rate of breast cancer cells to 9.78%. The small molecule peptide tablets prepared in Example 4 can reduce the survival rate of breast cancer cells to 13.16%.

[0072] 2. To verify the effect of Examples 1-4 on the migration rate of breast cancer cells, the experimental scheme is as follows: MCF-7 cells are plated on a 6-well plate at 5×10 4 The cells were cultured at a density of 10 cells / well for 48 h. After reaching a density of 80%, the culture medium was aspirated, the cell monolayer was scraped with a 10 uL sterile pipette tip, and then gently washed with PBS to remove cell debris. Then, the cells were incubated with Examples 1-4, respectively, and their migration along the injury line was observed under a microscope. Cell images (5x magnification) were captured after 0 h, 24 h, and 48 h of incubation and analyzed using ImageJ software (Maryland, USA). The results are shown in Figure 4 .

[0073] Compared with the control group, the small molecule peptide tablets prepared in Example 1 can reduce the migration rate of breast cancer cells to 3.82%. The small molecule peptide tablets prepared in Example 2 can reduce the migration rate of breast cancer cells to 11.34%. The small molecule peptide tablets provided in Example 3 can reduce the migration rate of breast cancer cells to 5.26%. The small molecule peptide tablets prepared in Example 4 can reduce the migration rate of breast cancer cells to 6.03%.

[0074] 3. To verify the effects of Examples 1-4 on the swimming time and grip strength of tumor-bearing mice, the experimental protocol was as follows: BALB / c mice, female, 18-22 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. The mice were kept at 25±1°C, with a 12-h light / dark cycle, and had free access to water and food, a standard pellet diet, usually various grains or cereal foods made from ingredients such as soybean meal, corn meal, fish meal, and animal by-products. All experimental protocols were approved by the Animal Ethics Committee of Shenzhen Second People's Hospital and were carried out in accordance with the Principles for the Care and Use of Laboratory Animals in Research (State Council of China, 1988).

[0075] Before the establishment of the cancer-induced fatigue animal model, mice were subjected to a weight-bearing swimming test, and the mice with the longest and shortest swimming time were eliminated. 6 cells / 0.1 mL / mouse) were injected subcutaneously into the second mammary fat pad on the left side of the mouse. When the tumor size reached 80-100 mm 3 Start treatment when

[0076] 50 mice were randomly assigned to five treatment groups (10 mice in each group). Model group: Oral administration of 0.9% saline every day, the average weight of mice before treatment was 24.81g. Group 1: Oral administration of the small molecule peptide tablets prepared in Example 1 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 25.05g. Group 2: Oral administration of the small molecule peptide tablets prepared in Example 2 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 25.46g. Group 3: Oral administration of the shaped small molecule peptide tablets prepared in Example 3 every day, 200 mg per kilogram of body weight for each mouse, and the average weight of mice before treatment was 24.58g. Group 4: Oral administration of the small molecule peptide tablets prepared in Example 4 every day, 200 mg per kilogram of body weight for each mouse, the treatment time was 13d, and the average weight of mice before treatment was 24.79g.

[0077] After 13 days of treatment, the average body weights of mice in groups 1 to 4 and the model group were measured: the average body weight of mice in group 1 was 29.63 g, the average body weight of mice in group 2 was 29.23 g, the average body weight of mice in group 3 was 29.21 g, the average body weight of mice in group 4 was 28.52 g, and the average body weight of mice in the model group was 27.60 g.

[0078] Swimming time measurement: After 13 days of treatment, mice in groups 1 to 4 and the model group were loaded with lead blocks accounting for 5% of their body weight and placed individually in a swimming pool (0.5m×0.5m×0.4m) filled with water (maintained at 25±2℃) to a depth of 0.35m. The swimming endurance time from the start of swimming to the mice being unable to return to the water surface within 8s was measured.

[0079] Grip strength measurement: After 13 days of treatment, grip strength was assessed using a grip strength meter (YLS-13A) (Y.-J. Chen, R. Baskaran, Ma Shibu, & W.-T. Lin, 2022). Mice in groups 1 to 4 and the model group grasped the pull rod on the grip line with their front paws, gently pulled the mouse's tail upward, and then the instrument automatically recorded the peak grip strength. Results are shown in Figure 5 and Figure 6 .

[0080] The swimming time of the tumor-bearing mice in the model group was 9.02 min; the swimming time of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 1 was 24.66 min; the swimming time of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 2 was 15.16 min; the swimming time of the tumor-bearing mice fed with the small molecule peptide tablets provided in Example 3 was 17.97 min; and the swimming time of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 4 was 22.62 min.

[0081] The grip strength of the tumor-bearing mice in the model group was 84.78 g; the grip strength of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 1 was 134.27 g; the grip strength of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 2 was 97.69 g; the grip strength of the tumor-bearing mice fed with the small molecule peptide tablets provided in Example 3 was 109.1 g; the grip strength of the tumor-bearing mice fed with the small molecule peptide tablets prepared in Example 4 was 127.53 g.

[0082] 5. To verify the effect of Examples 1-4 on tumor weight, the tumor weight determination scheme is as follows: After 13 days of treatment, the mice in Groups 1-4 and the model group were killed and the tumors were removed and weighed. Figure 7 .

[0083] The tumor weight of mice in the model group was 1.28 g; the tumor weight of mice fed with the small molecule peptide tablets prepared in Example 1 was 0.93 g; the tumor weight of mice fed with the small molecule peptide tablets prepared in Example 2 was 1.12 g; the tumor weight of mice fed with the small molecule peptide tablets prepared in Example 3 was 0.96 g; the tumor weight of mice fed with the small molecule peptide tablets prepared in Example 4 was 1.01 g.

[0084] 6. Verify the effect of Examples 1-4 on tumor inhibition rate, the calculation formula is as follows: Tumor inhibition rate = (AB) / A * 100%, where A and B are the average tumor weights of mice in the model group and the corresponding treatment group after 13 days of treatment, respectively. The results are as follows Figure 8 .

[0085] like Figure 8As shown, the tumor inhibition rate of mice fed with the small molecule peptide tablets prepared in Example 1 was 26.54%; the tumor inhibition rate of mice fed with the small molecule peptide tablets prepared in Example 2 was 12.00%; the tumor inhibition rate of mice fed with the small molecule peptide tablets prepared in Example 3 was 25.05%; and the tumor inhibition rate of mice fed with the small molecule peptide tablets prepared in Example 4 was 20.02%.

[0086] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. A method for preparing a small molecule peptide tablet for preventing breast cancer and breast cancer-induced fatigue, characterized in that: The following steps are involved: S1, construction of dipeptide structure; S2. Predict potential targets of dipeptides; S3. Find information on targets for breast cancer and fatigue-related diseases; S4, taking the intersection of the breast cancer and fatigue-related disease targets found in step S3 and the 400 dipeptide targets in step S2, obtaining 400 potential disease targets of small peptides, and finally screening out cancer-related targets and fatigue-related targets; S5. Use molecular docking method to screen active peptides with inhibitory effects on targets related to breast cancer and breast cancer-induced fatigue; S6, synthesis of small molecule peptides; S7. Preparation of small molecule peptide tablets.

2. The preparation method according to claim 1, characterized in that: In step S1, 400 dipeptide structures were constructed using ChemDraw and Chem3D.

3. The preparation method according to claim 1, characterized in that: In step S2, Pharmmapper software was used to predict potential dipeptide targets, and 400 dipeptide targets were obtained.

4. The preparation method according to claim 1, characterized in that: In step S3, all target information of breast cancer and fatigue-related diseases was searched through GeneCards, OMIM, DisGeNET and TTD websites.

5. The preparation method according to claim 1, characterized in that: The cancer-related targets finally screened out in step S4 were APAF1, BTK, INSR, and RAC1, and the fatigue-related targets were BTK, INSR, SELE, and SRC.

6. The preparation method according to claim 1, characterized in that: In S5, the molecular docking method was used to screen active peptides with inhibitory potential on breast cancer and breast cancer-induced fatigue-related targets, including the following steps: (1) Acquisition of 3D structures: The 3D structures of APAF1, BTK, INSR, RAC1, SELE, and SRC were obtained from the RCSB database; (2) Molecular docking: After removing ligands and water molecules from APAF1, BTK, INSR, RAC1, SELE, and SRC in step (1), nonpolar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S1, and semi-flexible molecular docking of peptide with APAF1, peptide with BTK, peptide with INSR, peptide with RAC1, peptide with SELE, and peptide with SRC was performed using AutoDock 4.2 software; (3) After molecular docking, active peptides that showed the best binding to breast cancer and breast cancer-induced fatigue-related targets were screened out based on the binding energy results.

7. The preparation method according to claim 1, characterized in that: The anti-fatigue active peptides screened in S5 were FD, WD, EW, RE, PE, LD, WE, IE, YE, and YD; The anticancer peptides are FD, WD, RE, YD, RD, EW, CD, PD, ED, and EE.

8. The preparation method according to claim 1, characterized in that: In S6, the active peptides screened in step S5 are synthesized into small molecule peptides using the Fmoc solid phase synthesis method.

9. The preparation method according to claim 1, characterized in that: In S7, one or more of the small molecule peptides synthesized in S6 are mixed with γ-aminobutyric acid, egg yolk lecithin, resveratrol, grape seed extract, and dextrin.

10. The small molecule peptide tablets for preventing breast cancer and breast cancer-induced fatigue prepared by the preparation method according to any one of claims 1 to 9.

Citation Information

Patent Citations

  • Application of oyster active peptide in preparation of anti-diabetes medicine

    CN116925181A

Cited By

  • Ed peptide, or a pharmaceutically acceptable salt thereof, for treating urolithiasis

    EP4789678A1

  • Ed peptide, or a pharmaceutically acceptable salt thereof, for treating urolithiasis

    WO2026171706A1